Literature DB >> 30636397

Ixekizumab in hidradenitis suppurativa in a psoriatic patient.

Giulia Odorici1, Giovanni Pellacani2, Andrea Conti2.   

Abstract

Entities:  

Year:  2019        PMID： 30636397     DOI： 10.23736/S0392-0488.18.06135-7

Source DB:  PubMed          Journal:  G Ital Dermatol Venereol        ISSN： 0392-0488            Impact factor:   2.011


× No keyword cloud information.
  5 in total

1.  An Anti-Interleukin-17A Monoclonal Antibody, Ixekizumab, in the Treatment of Resistant Hidradenitis Suppurativa: A Case Series.

Authors:  Pelin Esme; Aysenur Botsali; Gulsen Akoglu; Ercan Caliskan
Journal:  Skin Appendage Disord       Date:  2022-02-09

2.  The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: An open-label cohort study.

Authors:  John W Frew; Kristina Navrazhina; David Grand; Mary Sullivan-Whalen; Patricia Gilleaudeau; Sandra Garcet; Jonathan Ungar; James G Krueger
Journal:  J Am Acad Dermatol       Date:  2020-05-13       Impact factor: 11.527

Review 3.  Paradoxical Hidradenitis Suppurativa during Biologic Therapy, an Emerging Challenge: A Systematic Review.

Authors:  Angelo Ruggiero; Fabrizio Martora; Vincenzo Picone; Laura Marano; Gabriella Fabbrocini; Claudio Marasca
Journal:  Biomedicines       Date:  2022-02-16

Review 4.  New and Emerging Targeted Therapies for Hidradenitis Suppurativa.

Authors:  Adela Markota Čagalj; Branka Marinović; Zrinka Bukvić Mokos
Journal:  Int J Mol Sci       Date:  2022-03-29       Impact factor: 5.923

Review 5.  Immunomodulatory Drugs in the Treatment of Hidradenitis Suppurativa-Possibilities and Limitations.

Authors:  Zuzanna Świerczewska; Miłosz Lewandowski; Agnieszka Surowiecka; Wioletta Barańska-Rybak
Journal:  Int J Mol Sci       Date:  2022-08-26       Impact factor: 6.208
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.